Oncology Biosimilar Market To Report Impressive Growth, Revenue To Surge To USD 28.26 Billion By 2032

With the presence of a large pool of participants, the global oncology Biosimilar market is displaying a highly competitive business landscape, finds a new research report by Zion Market Research (ZMR). Teva Pharmaceutical Industries Ltd., Biocon, STADA Arzneimittel AG, Sandoz International GmbH, Intas Pharmaceuticals Ltd., Celltrion Inc., Pfizer Inc., Apotex Inc., Dr. Reddy’s Laboratories Ltd., and BIOCAD are some of the key vendors of oncology Biosimilar across the world. These players are focusing aggressively on innovation, as well as on including advanced technologies in their existing products. Over the coming years, they are also expected to take up partnerships and mergers and acquisitions as their key strategy for business development, states the oncology Biosimilar market study.

This review is based on a report by Zion Market Research, titled “Oncology Biosimilar Market By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, And Others), By Drug Type (MAb, Immunomodulators, Hematopoietic Agents, G-CSF, And Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacy, And Online Pharmacy), And By Region - Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2024–2032”-Report at https://www.zionmarketresearch.com/report/oncology-biosimilar-market

Reportedly, in October 2018, Oncologic Drugs Advisory Committee division of the U.S. FDA recommended the approving of Rituximab Biosimilar CT-P10 for three of the anti-CD20 monoclonal antibodies for Non-Hodgkin B-cell lymphoma indications.

In another instance, in October 2018, Health Canada – the department of the government of Canada with responsibility for national public health ­– approved Trastuzumab formulation for subcutaneous administration. Reportedly, the drug Trastuzumab sold under Herceptin brand for treating HER2-positive cancer types can be administered in patients for nearly two to five minutes.

As estimated in this report, the global oncology biosimilar market size was worth around USD 6.13 billion in 2023 and is predicted to grow to around USD 28.26 billion by 2032 with a compound annual growth rate (CAGR) of roughly 18.50% between 2024 and 2032. The main drug types available in this oncology Biosimilar market are mAb, Immunomodulators, Hematopoietic Agents, G-CSF, and Others. Among them, the demand for G-CSF is relatively higher and the trend is anticipated to remain so over the next few years, notes the oncology Biosimilar market research report.

Growing Cancer Cases To Soar Oncology Biosimilar Market Earnings

“Oncology Biosimilar market is anticipated to gain traction over the years ahead, owing to growing incidences of cancer resulting in tremendous demand for cost-effective cancer therapies,” says the author of this study. Apart from this, rise in approval of biosimilars along with escalating need for improved healthcare amenities is anticipated to further drive oncology Biosimilar market trends. In addition, patent expiry is likely to provide lucrative growth avenues for oncology Biosimilar market in the near future.

Humungous Demand For Oncology Biosimilar To Aid Regional Dominance

Regionally, North America has been leading the worldwide oncology Biosimilar market and is anticipated to continue on the dominant position in the years to come, states the oncology Biosimilar market study. Massive demand for oncology biologics is the main factor behind the dominance of the North America oncology Biosimilar market. The high number of market players being headquartered in North America is another significant factor that is supporting this regional oncology Biosimilar market. In addition, increase in the approval of biosimilars by the U.S. FDA along with growing frequency of cancer in the countries such as the U.S. will significantly contribute towards the growth of oncology Biosimilar market in North America.  

The global oncology biosimilar market is segmented as follows:

By Test Type

• Breast Cancer
• Colorectal Cancer
• Blood Cancer
• Neutropenia Cancer
• Non-Small Cell Lung Cancer 
• Others

By Drug Type

• mAb
• Immunomodulators
• Hematopoietic Agents
• G-CSF 
• Others

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacy
• Online Pharmacy

By Region

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com